Since the isolation of SARS-CoV-2 and the study of its infection mechanisms, scientists have been trying to understand how this virus accesses the brain and produces neurological symptoms.
A study published in Nature Communications revealed a new antisense oligonucleotide therapy applicable to the W1282X mutation of the cystic fibrosis transmembrane conductance regulator gene in cystic fibrosis.
